Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Cash from Investing Activities (2023 - 2025)

NewAmsterdam Pharma's Cash from Investing Activities history spans 3 years, with the latest figure at -$21.1 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 66.0% year-over-year to -$21.1 million; the TTM value through Dec 2025 reached -$174.9 million, down 178.32%, while the annual FY2025 figure was -$174.9 million, 178.32% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$21.1 million at NewAmsterdam Pharma, down from $2.5 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $2.9 million in Q1 2025 and bottomed at -$159.1 million in Q2 2025.
  • The 3-year median for Cash from Investing Activities is -$42000.0 (2023), against an average of -$19.8 million.
  • The largest annual shift saw Cash from Investing Activities tumbled 2072533.33% in 2024 before it skyrocketed 3441.33% in 2025.
  • A 3-year view of Cash from Investing Activities shows it stood at -$3000.0 in 2023, then crashed by 2072533.33% to -$62.2 million in 2024, then skyrocketed by 66.0% to -$21.1 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Cash from Investing Activities are -$21.1 million (Q4 2025), $2.5 million (Q3 2025), and -$159.1 million (Q2 2025).